Actinium Pharmaceuticals (ATNM) EBITDA Margin (2021 - 2026)

Actinium Pharmaceuticals (ATNM) posted quarterly EBITDA Margin of 6324.44% for Q3 2025, up 70.96% quarter-over-quarter from 21775.56% in Q3 2022.

Actinium Pharmaceuticals (ATNM) EBITDA Margin (2021 - 2026) Analysis & Trends

Actinium Pharmaceuticals (ATNM) has reported EBITDA Margin for 3 consecutive years, with 6324.44% the latest figure, recorded in Q3 2025.

In Q3 2025, EBITDA Margin changed N/A year-over-year to 6324.44%; the TTM figure through Dec 2025 stood at 26849.63% (changed N/A YoY), while the FY2025 annual figure was 40274.44%, changed N/A from the prior year.
EBITDA Margin grew to 6324.44% in Q3 2025 per ATNM's latest filing, from 21775.56% in the prior quarter.
Across five years, EBITDA Margin topped out at 549.36% in Q1 2022 and bottomed at 34991.3% in Q4 2021.
Historically, EBITDA Margin has averaged 10829.13% across 3 years, with a median of 4550.42% in 2025.
On a YoY basis, EBITDA Margin climbed as much as 31430 bps in 2022 and fell as far as 1899916 bps in 2022.
Actinium Pharmaceuticals' EBITDA Margin stood at 34991.3% in 2021, then jumped by 38 bps to 21775.56% in 2022, then jumped by 71 bps to 6324.44% in 2025.
Business Quant data shows ATNM's EBITDA Margin at 6324.44% in Q3 2025, 21775.56% in Q3 2022, and 17444.44% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	139.96 Bn	132.11 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.79 Bn	78.79 Bn	3.93 Bn	30.15%
3	Argenx Se	65.22 Bn	60.03 Bn	1.37 Bn	32.54%
4	Moderna	60.20 Bn	55.06 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.19 Bn	37.09 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.43 Bn	28.12 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.65 Bn	10.26 Bn	668.28 Mn	-35.57%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.16 Bn	26.32 Bn	-	19.75%
10	Actinium Pharmaceuticals	35.74 Mn	35.74 Mn	-	78.76%

Download Data